Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00522249

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

A Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic Renal Cell Carcinoma

Sponsor: Schering-Plough

Interventions Pegylated Alfa Interferon erlotinib sunitinib

Updated 6 times since 2017 Last updated: Mar 15, 2016 Started: May 31, 2007 Primary completion: May 31, 2008 Completion: Jul 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI decision

Other terminated trials from Schering-Plough

See all terminations from Schering-Plough

Other Carcinoma, Renal Cell trials with similar outcome

Browse all Carcinoma, Renal Cell trials

This PHASE1/PHASE2 trial investigates Carcinoma, Renal Cell and is currently terminated or withdrawn. Schering-Plough leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Oct 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Oct 2021 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Schering-Plough
The Methodist Hospital Research Institute

Data source: The Methodist Hospital Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States